Eli Lilly: conclusive trial for lebrikizumab in eczema

(CercleFinance.com) - Eli Lilly has presented the results of a Phase III study of lebrikizumab as a treatment for eczema in non-white people.
In this study, the treatment showed an improvement in skin clearance and relief from itching.

The results of this trial are consistent with data from other phase 3 studies

With these initial results, Lilly is taking a step forward in addressing the needs of people with colored skin affected by atopic dermatitis, said the study's principal investigator.

Through clinical trials like this one, we hope to achieve more breakthroughs to improve the lives of the underserved, Eli Lilly added.


Copyright (c) 2024 CercleFinance.com. All rights reserved.